{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13(8)"],"submitter":["Ras-Jimenez MDM"],"pubmed_abstract":["The soluble transferrin receptor (sTfR) is a marker of tissue iron status, which could indicate an increased iron demand at the tissue level. The impact of sTfR levels on functional capacity and quality of life (QoL) in non-anemic heart failure (HF) patients with otherwise normal systemic iron status has not been evaluated. We conducted an observational, prospective, cohort study of 1236 patients with chronic HF. We selected patients with normal hemoglobin levels and normal systemic iron status. Tissue iron deficiency (ID) was defined as levels of sTfR > 75th percentile (1.63 mg per L). The primary endpoints were the distance walked in the 6 min walking test (6MWT) and the overall summary score (OSS) of the Minnesota Living with Heart Failure Questionnaire (MLHFQ). The final study cohort c"],"journal":["Journal of personalized medicine"],"pagination":["1282"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10455097"],"repository":["biostudies-literature"],"pubmed_title":["Soluble Transferrin Receptor as Iron Deficiency Biomarker: Impact on Exercise Capacity in Heart Failure Patients."],"pmcid":["PMC10455097"],"pubmed_authors":["de Frutos Seminario F","Yun Viladomat S","Tajes Orduna M","Torres Cardus B","Triguero-Llonch L","Comin-Colet J","Ramos-Polo R","Francesch Manzano J","Moliner Borja P","Verdu-Rotellar JM","Garcia-Romero E","Enjuanes Grau C","Ras-Jimenez MDM","Diez-Lopez C","Morillas Climent H","Corbella Santano M","Garcimartin Cerezo P","Gonzalez-Costello J","Jose-Bazan N","Jimenez-Marrero S"],"additional_accession":[]},"is_claimable":false,"name":"Soluble Transferrin Receptor as Iron Deficiency Biomarker: Impact on Exercise Capacity in Heart Failure Patients.","description":"The soluble transferrin receptor (sTfR) is a marker of tissue iron status, which could indicate an increased iron demand at the tissue level. The impact of sTfR levels on functional capacity and quality of life (QoL) in non-anemic heart failure (HF) patients with otherwise normal systemic iron status has not been evaluated. We conducted an observational, prospective, cohort study of 1236 patients with chronic HF. We selected patients with normal hemoglobin levels and normal systemic iron status. Tissue iron deficiency (ID) was defined as levels of sTfR > 75th percentile (1.63 mg per L). The primary endpoints were the distance walked in the 6 min walking test (6MWT) and the overall summary score (OSS) of the Minnesota Living with Heart Failure Questionnaire (MLHFQ). The final study cohort c","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Aug","modification":"2025-04-05T13:37:43.797Z","creation":"2025-04-05T13:37:43.797Z"},"accession":"S-EPMC10455097","cross_references":{"pubmed":["37623532"],"doi":["10.3390/jpm13081282"]}}